+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-cd20 Monoclonal Antibodies (mabs) Market 2025-2029- Product Image
Anti-cd20 Monoclonal Antibodies (mabs) Market 2025-2029- Product Image
New

Anti-cd20 Monoclonal Antibodies (mabs) Market 2025-2029

  • PDF Icon

    Report

  • 255 Pages
  • March 2025
  • Region: Global
  • TechNavio
  • ID: 5574258
1h Free Analyst Time
REQUEST FREE SAMPLE
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The anti-CD20 monoclonal antibodies (MABs) market is forecasted to grow by USD 15.64 billion during 2024-2029, accelerating at a CAGR of 12.3% during the forecast period. The report on the anti-CD20 monoclonal antibodies (MABs) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increased use of combination therapies, high target affinity and specificity of anti-CD20 MABs, and strong pipeline and recent approvals.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

The anti-CD20 monoclonal antibodies (MABs) market is segmented as below:

By Product

  • Oncology
  • Neurology
  • Immunology

By Type

  • First generation
  • Second generation
  • Third generation

By End-user

  • Hospitals and clinics
  • Academic and research institutions
  • Contract research organizations

By Drug Class

  • Rituximab
  • Ofatumumab
  • Obinutuzumab
  • Ublituximab
  • Others

By Route Of Administration

  • Intravenous
  • Subcutaneous

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the increasing awareness about therapeutic areas as one of the prime reasons driving the anti-CD20 monoclonal antibodies (MABs) market growth during the next few years. Also, presence of reimbursement and patient assistance programs and the development of CD20 bispecific antibodies will lead to sizable demand in the market.

The report on the anti-CD20 monoclonal antibodies (MABs) market covers the following areas:

  • Anti-CD20 Monoclonal Antibodies (MABs) Market sizing
  • Anti-CD20 Monoclonal Antibodies (MABs) Market forecast
  • Anti-CD20 Monoclonal Antibodies (MABs) Market industry analysis
A robust vendor analysis within the report is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-cd20 monoclonal antibodies (MABs) market vendors that include Acrotech Biopharma Inc., Amgen Inc., AstraZeneca PLC, Celltrion Healthcare Co. Ltd., F. Hoffmann La Roche Ltd., Fosun International Ltd., Genmab AS, IGM Biosciences Inc., JSC BIOCAD, LFB SA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Spectrum Pharmaceuticals Inc., TG Therapeutics Inc., United BioPharma Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd. Also, the anti-CD20 monoclonal antibodies (MABs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Executive Summary - Chart on Market Overview
Executive Summary - Data Table on Market Overview
Executive Summary - Chart on Global Market Characteristics
Executive Summary - Chart on Market By Geographical Landscape
Executive Summary - Chart on Market Segmentation by Product
Executive Summary - Chart on Market Segmentation by Type
Executive Summary - Chart on Market Segmentation by End-user
Executive Summary - Chart on Market Segmentation by Drug Class
Executive Summary - Chart on Market Segmentation by Route of Administration
Executive Summary - Chart on Incremental Growth
Executive Summary - Data Table on Incremental Growth
Executive Summary - Chart on Company Market Positioning
2 Market Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
Overview on factors of disruption
2.4 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
3.1 Market ecosystem
Parent Market
Data Table on - Parent Market
3.2 Market characteristics
Market characteristics analysis
3.3 Value chain analysis
Value chain analysis
4 Market Sizing
4.1 Market definition
Offerings of companies included in the market definition
4.2 Market segment analysis
Market segments
4.3 Market size 2024
4.4 Market outlook: Forecast for 2024-2029
Chart on Global - Market size and forecast 2024-2029 ($ million)
Data Table on Global - Market size and forecast 2024-2029 ($ million)
Chart on Global Market: Year-over-year growth 2024-2029 (%)
Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
5.1 Global Anti-CD20 Monoclonal Antibodies (MABs) Market 2019 - 2023
Historic Market Size - Data Table on Global Anti-CD20 Monoclonal Antibodies (MABs) Market 2019 - 2023 ($ million)
5.2 Product segment analysis 2019 - 2023
Historic Market Size - Product Segment 2019 - 2023 ($ million)
5.3 Type segment analysis 2019 - 2023
Historic Market Size - Type Segment 2019 - 2023 ($ million)
5.4 End-user segment analysis 2019 - 2023
Historic Market Size - End-user Segment 2019 - 2023 ($ million)
5.5 Drug Class segment analysis 2019 - 2023
Historic Market Size - Drug Class Segment 2019 - 2023 ($ million)
5.6 Route of Administration segment analysis 2019 - 2023
Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
5.7 Geography segment analysis 2019 - 2023
Historic Market Size - Geography Segment 2019 - 2023 ($ million)
5.8 Country segment analysis 2019 - 2023
Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
6.1 Impact of AI on global anti-CD20 monoclonal antibodies (mABs) market
7 Five Forces Analysis
7.1 Five forces summary
Five forces analysis - Comparison between 2024 and 2029
7.2 Bargaining power of buyers
Bargaining power of buyers - Impact of key factors 2024 and 2029
7.3 Bargaining power of suppliers
Bargaining power of suppliers - Impact of key factors in 2024 and 2029
7.4 Threat of new entrants
Threat of new entrants - Impact of key factors in 2024 and 2029
7.5 Threat of substitutes
Threat of substitutes - Impact of key factors in 2024 and 2029
7.6 Threat of rivalry
Threat of rivalry - Impact of key factors in 2024 and 2029
7.7 Market condition
Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Product
8.1 Market segments
Chart on Product - Market share 2024-2029 (%)
Data Table on Product - Market share 2024-2029 (%)
8.2 Comparison by Product
Chart on Comparison by Product
Data Table on Comparison by Product
8.3 Oncology - Market size and forecast 2024-2029
Chart on Oncology - Market size and forecast 2024-2029 ($ million)
Data Table on Oncology - Market size and forecast 2024-2029 ($ million)
Chart on Oncology - Year-over-year growth 2024-2029 (%)
Data Table on Oncology - Year-over-year growth 2024-2029 (%)
8.4 Neurology - Market size and forecast 2024-2029
Chart on Neurology - Market size and forecast 2024-2029 ($ million)
Data Table on Neurology - Market size and forecast 2024-2029 ($ million)
Chart on Neurology - Year-over-year growth 2024-2029 (%)
Data Table on Neurology - Year-over-year growth 2024-2029 (%)
8.5 Immunology - Market size and forecast 2024-2029
Chart on Immunology - Market size and forecast 2024-2029 ($ million)
Data Table on Immunology - Market size and forecast 2024-2029 ($ million)
Chart on Immunology - Year-over-year growth 2024-2029 (%)
Data Table on Immunology - Year-over-year growth 2024-2029 (%)
8.6 Market opportunity by Product
Market opportunity by Product ($ million)
Data Table on Market opportunity by Product ($ million)
9 Market Segmentation by Type
9.1 Market segments
Chart on Type - Market share 2024-2029 (%)
Data Table on Type - Market share 2024-2029 (%)
9.2 Comparison by Type
Chart on Comparison by Type
Data Table on Comparison by Type
9.3 First generation - Market size and forecast 2024-2029
Chart on First generation - Market size and forecast 2024-2029 ($ million)
Data Table on First generation - Market size and forecast 2024-2029 ($ million)
Chart on First generation - Year-over-year growth 2024-2029 (%)
Data Table on First generation - Year-over-year growth 2024-2029 (%)
9.4 Second generation - Market size and forecast 2024-2029
Chart on Second generation - Market size and forecast 2024-2029 ($ million)
Data Table on Second generation - Market size and forecast 2024-2029 ($ million)
Chart on Second generation - Year-over-year growth 2024-2029 (%)
Data Table on Second generation - Year-over-year growth 2024-2029 (%)
9.5 Third generation - Market size and forecast 2024-2029
Chart on Third generation - Market size and forecast 2024-2029 ($ million)
Data Table on Third generation - Market size and forecast 2024-2029 ($ million)
Chart on Third generation - Year-over-year growth 2024-2029 (%)
Data Table on Third generation - Year-over-year growth 2024-2029 (%)
9.6 Market opportunity by Type
Market opportunity by Type ($ million)
Data Table on Market opportunity by Type ($ million)
10 Market Segmentation by End-user
10.1 Market segments
Chart on End-user - Market share 2024-2029 (%)
Data Table on End-user - Market share 2024-2029 (%)
10.2 Comparison by End-user
Chart on Comparison by End-user
Data Table on Comparison by End-user
10.3 Hospitals and clinics - Market size and forecast 2024-2029
Chart on Hospitals and clinics - Market size and forecast 2024-2029 ($ million)
Data Table on Hospitals and clinics - Market size and forecast 2024-2029 ($ million)
Chart on Hospitals and clinics - Year-over-year growth 2024-2029 (%)
Data Table on Hospitals and clinics - Year-over-year growth 2024-2029 (%)
10.4 Academic and research institutions - Market size and forecast 2024-2029
Chart on Academic and research institutions - Market size and forecast 2024-2029 ($ million)
Data Table on Academic and research institutions - Market size and forecast 2024-2029 ($ million)
Chart on Academic and research institutions - Year-over-year growth 2024-2029 (%)
Data Table on Academic and research institutions - Year-over-year growth 2024-2029 (%)
10.5 Contract research organizations - Market size and forecast 2024-2029
Chart on Contract research organizations - Market size and forecast 2024-2029 ($ million)
Data Table on Contract research organizations - Market size and forecast 2024-2029 ($ million)
Chart on Contract research organizations - Year-over-year growth 2024-2029 (%)
Data Table on Contract research organizations - Year-over-year growth 2024-2029 (%)
10.6 Market opportunity by End-user
Market opportunity by End-user ($ million)
Data Table on Market opportunity by End-user ($ million)
11 Market Segmentation by Drug Class
11.1 Market segments
Chart on Drug Class - Market share 2024-2029 (%)
Data Table on Drug Class - Market share 2024-2029 (%)
11.2 Comparison by Drug Class
Chart on Comparison by Drug Class
Data Table on Comparison by Drug Class
11.3 Rituximab - Market size and forecast 2024-2029
Chart on Rituximab - Market size and forecast 2024-2029 ($ million)
Data Table on Rituximab - Market size and forecast 2024-2029 ($ million)
Chart on Rituximab - Year-over-year growth 2024-2029 (%)
Data Table on Rituximab - Year-over-year growth 2024-2029 (%)
11.4 Ofatumumab - Market size and forecast 2024-2029
Chart on Ofatumumab - Market size and forecast 2024-2029 ($ million)
Data Table on Ofatumumab - Market size and forecast 2024-2029 ($ million)
Chart on Ofatumumab - Year-over-year growth 2024-2029 (%)
Data Table on Ofatumumab - Year-over-year growth 2024-2029 (%)
11.5 Obinutuzumab - Market size and forecast 2024-2029
Chart on Obinutuzumab - Market size and forecast 2024-2029 ($ million)
Data Table on Obinutuzumab - Market size and forecast 2024-2029 ($ million)
Chart on Obinutuzumab - Year-over-year growth 2024-2029 (%)
Data Table on Obinutuzumab - Year-over-year growth 2024-2029 (%)
11.6 Ublituximab - Market size and forecast 2024-2029
Chart on Ublituximab - Market size and forecast 2024-2029 ($ million)
Data Table on Ublituximab - Market size and forecast 2024-2029 ($ million)
Chart on Ublituximab - Year-over-year growth 2024-2029 (%)
Data Table on Ublituximab - Year-over-year growth 2024-2029 (%)
11.7 Others - Market size and forecast 2024-2029
Chart on Others - Market size and forecast 2024-2029 ($ million)
Data Table on Others - Market size and forecast 2024-2029 ($ million)
Chart on Others - Year-over-year growth 2024-2029 (%)
Data Table on Others - Year-over-year growth 2024-2029 (%)
11.8 Market opportunity by Drug Class
Market opportunity by Drug Class ($ million)
Data Table on Market opportunity by Drug Class ($ million)
12 Market Segmentation by Route of Administration
12.1 Market segments
Chart on Route of Administration - Market share 2024-2029 (%)
Data Table on Route of Administration - Market share 2024-2029 (%)
12.2 Comparison by Route of Administration
Chart on Comparison by Route of Administration
Data Table on Comparison by Route of Administration
12.3 Intravenous - Market size and forecast 2024-2029
Chart on Intravenous - Market size and forecast 2024-2029 ($ million)
Data Table on Intravenous - Market size and forecast 2024-2029 ($ million)
Chart on Intravenous - Year-over-year growth 2024-2029 (%)
Data Table on Intravenous - Year-over-year growth 2024-2029 (%)
12.4 Subcutaneous - Market size and forecast 2024-2029
Chart on Subcutaneous - Market size and forecast 2024-2029 ($ million)
Data Table on Subcutaneous - Market size and forecast 2024-2029 ($ million)
Chart on Subcutaneous - Year-over-year growth 2024-2029 (%)
Data Table on Subcutaneous - Year-over-year growth 2024-2029 (%)
12.5 Market opportunity by Route of Administration
Market opportunity by Route of Administration ($ million)
Data Table on Market opportunity by Route of Administration ($ million)
13 Customer Landscape
13.1 Customer landscape overview
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
14 Geographic Landscape
14.1 Geographic segmentation
Chart on Market share By Geographical Landscape 2024-2029 (%)
Data Table on Market share By Geographical Landscape 2024-2029 (%)
14.2 Geographic comparison
Chart on Geographic comparison
Data Table on Geographic comparison
14.3 North America - Market size and forecast 2024-2029
Chart on North America - Market size and forecast 2024-2029 ($ million)
Data Table on North America - Market size and forecast 2024-2029 ($ million)
Chart on North America - Year-over-year growth 2024-2029 (%)
Data Table on North America - Year-over-year growth 2024-2029 (%)
14.4 Europe - Market size and forecast 2024-2029
Chart on Europe - Market size and forecast 2024-2029 ($ million)
Data Table on Europe - Market size and forecast 2024-2029 ($ million)
Chart on Europe - Year-over-year growth 2024-2029 (%)
Data Table on Europe - Year-over-year growth 2024-2029 (%)
14.5 Asia - Market size and forecast 2024-2029
Chart on Asia - Market size and forecast 2024-2029 ($ million)
Data Table on Asia - Market size and forecast 2024-2029 ($ million)
Chart on Asia - Year-over-year growth 2024-2029 (%)
Data Table on Asia - Year-over-year growth 2024-2029 (%)
14.6 Rest of World (ROW) - Market size and forecast 2024-2029
Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
14.7 US - Market size and forecast 2024-2029
Chart on US - Market size and forecast 2024-2029 ($ million)
Data Table on US - Market size and forecast 2024-2029 ($ million)
Chart on US - Year-over-year growth 2024-2029 (%)
Data Table on US - Year-over-year growth 2024-2029 (%)
14.8 Canada - Market size and forecast 2024-2029
Chart on Canada - Market size and forecast 2024-2029 ($ million)
Data Table on Canada - Market size and forecast 2024-2029 ($ million)
Chart on Canada - Year-over-year growth 2024-2029 (%)
Data Table on Canada - Year-over-year growth 2024-2029 (%)
14.9 China - Market size and forecast 2024-2029
Chart on China - Market size and forecast 2024-2029 ($ million)
Data Table on China - Market size and forecast 2024-2029 ($ million)
Chart on China - Year-over-year growth 2024-2029 (%)
Data Table on China - Year-over-year growth 2024-2029 (%)
14.10 UK - Market size and forecast 2024-2029
Chart on UK - Market size and forecast 2024-2029 ($ million)
Data Table on UK - Market size and forecast 2024-2029 ($ million)
Chart on UK - Year-over-year growth 2024-2029 (%)
Data Table on UK - Year-over-year growth 2024-2029 (%)
14.11 Germany - Market size and forecast 2024-2029
Chart on Germany - Market size and forecast 2024-2029 ($ million)
Data Table on Germany - Market size and forecast 2024-2029 ($ million)
Chart on Germany - Year-over-year growth 2024-2029 (%)
Data Table on Germany - Year-over-year growth 2024-2029 (%)
14.12 Japan - Market size and forecast 2024-2029
Chart on Japan - Market size and forecast 2024-2029 ($ million)
Data Table on Japan - Market size and forecast 2024-2029 ($ million)
Chart on Japan - Year-over-year growth 2024-2029 (%)
Data Table on Japan - Year-over-year growth 2024-2029 (%)
14.13 India - Market size and forecast 2024-2029
Chart on India - Market size and forecast 2024-2029 ($ million)
Data Table on India - Market size and forecast 2024-2029 ($ million)
Chart on India - Year-over-year growth 2024-2029 (%)
Data Table on India - Year-over-year growth 2024-2029 (%)
14.14 Italy - Market size and forecast 2024-2029
Chart on Italy - Market size and forecast 2024-2029 ($ million)
Data Table on Italy - Market size and forecast 2024-2029 ($ million)
Chart on Italy - Year-over-year growth 2024-2029 (%)
Data Table on Italy - Year-over-year growth 2024-2029 (%)
14.15 France - Market size and forecast 2024-2029
Chart on France - Market size and forecast 2024-2029 ($ million)
Data Table on France - Market size and forecast 2024-2029 ($ million)
Chart on France - Year-over-year growth 2024-2029 (%)
Data Table on France - Year-over-year growth 2024-2029 (%)
14.16 South Korea - Market size and forecast 2024-2029
Chart on South Korea - Market size and forecast 2024-2029 ($ million)
Data Table on South Korea - Market size and forecast 2024-2029 ($ million)
Chart on South Korea - Year-over-year growth 2024-2029 (%)
Data Table on South Korea - Year-over-year growth 2024-2029 (%)
14.17 Market opportunity By Geographical Landscape
Market opportunity By Geographical Landscape ($ million)
Data Tables on Market opportunity By Geographical Landscape ($ million)
15 Drivers, Challenges, and Opportunity/Restraints
15.1 Market drivers
15.2 Market challenges
15.3 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
15.4 Market opportunities/restraints
16 Competitive Landscape
16.1 Overview
16.2 Competitive Landscape
Overview on criticality of inputs and factors of differentiation
16.3 Landscape disruption
Overview on factors of disruption
16.4 Industry risks
Impact of key risks on business
17 Competitive Analysis
17.1 Companies profiled
Companies covered
17.2 Company ranking index
Company ranking index
17.3 Market positioning of companies
Matrix on companies position and classification
17.4 Acrotech Biopharma Inc.
Acrotech Biopharma Inc. - Overview
Acrotech Biopharma Inc. - Product / Service
Acrotech Biopharma Inc. - Key offerings
SWOT
17.5 Amgen Inc.
Amgen Inc. - Overview
Amgen Inc. - Product / Service
Amgen Inc. - Key news
Amgen Inc. - Key offerings
SWOT
17.6 AstraZeneca Plc
AstraZeneca Plc - Overview
AstraZeneca Plc - Product / Service
AstraZeneca Plc - Key news
AstraZeneca Plc - Key offerings
SWOT
17.7 Celltrion Healthcare Co. Ltd.
Celltrion Healthcare Co. Ltd. - Overview
Celltrion Healthcare Co. Ltd. - Business segments
Celltrion Healthcare Co. Ltd. - Key offerings
Celltrion Healthcare Co. Ltd. - Segment focus
SWOT
17.8 F. Hoffmann La Roche Ltd.
F. Hoffmann La Roche Ltd. - Overview
F. Hoffmann La Roche Ltd. - Business segments
F. Hoffmann La Roche Ltd. - Key news
F. Hoffmann La Roche Ltd. - Key offerings
F. Hoffmann La Roche Ltd. - Segment focus
SWOT
17.9 Fosun International Ltd.
Fosun International Ltd. - Overview
Fosun International Ltd. - Business segments
Fosun International Ltd. - Key offerings
Fosun International Ltd. - Segment focus
SWOT
17.10 Genmab AS
Genmab AS - Overview
Genmab AS - Product / Service
Genmab AS - Key offerings
SWOT
17.11 IGM Biosciences Inc.
IGM Biosciences Inc. - Overview
IGM Biosciences Inc. - Product / Service
IGM Biosciences Inc. - Key offerings
SWOT
17.12 JSC BIOCAD
JSC BIOCAD - Overview
JSC BIOCAD - Product / Service
JSC BIOCAD - Key offerings
SWOT
17.13 LFB SA
LFB SA - Overview
LFB SA - Product / Service
LFB SA - Key offerings
SWOT
17.14 Novartis AG
Novartis AG - Overview
Novartis AG - Business segments
Novartis AG - Key news
Novartis AG - Key offerings
Novartis AG - Segment focus
SWOT
17.15 Pfizer Inc.
Pfizer Inc. - Overview
Pfizer Inc. - Product / Service
Pfizer Inc. - Key news
Pfizer Inc. - Key offerings
SWOT
17.16 Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc. - Overview
Regeneron Pharmaceuticals Inc. - Product / Service
Regeneron Pharmaceuticals Inc. - Key offerings
SWOT
17.17 Spectrum Pharmaceuticals Inc.
Spectrum Pharmaceuticals Inc. - Overview
Spectrum Pharmaceuticals Inc. - Product / Service
Spectrum Pharmaceuticals Inc. - Key offerings
SWOT
17.18 TG Therapeutics Inc.
TG Therapeutics Inc. - Overview
TG Therapeutics Inc. - Product / Service
TG Therapeutics Inc. - Key offerings
SWOT
18 Appendix
18.1 Scope of the report
18.2 Inclusions and exclusions checklist
Inclusions checklist
Exclusions checklist
18.3 Currency conversion rates for US$
Currency conversion rates for US$
18.4 Research methodology
Research methodology
18.5 Data procurement
Information sources
18.6 Data validation
Data validation
18.7 Validation techniques employed for market sizing
Validation techniques employed for market sizing
18.8 Data synthesis
Data synthesis
18.9 360 degree market analysis
360 degree market analysis
18.10 List of abbreviations
List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Product
Exhibits 6: Executive Summary - Chart on Market Segmentation by Type
Exhibits 7: Executive Summary - Chart on Market Segmentation by End-user
Exhibits 8: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits 9: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibits 10: Executive Summary - Chart on Incremental Growth
Exhibits 11: Executive Summary - Data Table on Incremental Growth
Exhibits 12: Executive Summary - Chart on Company Market Positioning
Exhibits 13: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 14: Overview on criticality of inputs and factors of differentiation
Exhibits 15: Overview on factors of disruption
Exhibits 16: Impact of drivers and challenges in 2024 and 2029
Exhibits 17: Parent Market
Exhibits 18: Data Table on - Parent Market
Exhibits 19: Market characteristics analysis
Exhibits 20: Value chain analysis
Exhibits 21: Offerings of companies included in the market definition
Exhibits 22: Market segments
Exhibits 23: Chart on Global - Market size and forecast 2024-2029 ($ million)
Exhibits 24: Data Table on Global - Market size and forecast 2024-2029 ($ million)
Exhibits 25: Chart on Global Market: Year-over-year growth 2024-2029 (%)
Exhibits 26: Data Table on Global Market: Year-over-year growth 2024-2029 (%)
Exhibits 27: Historic Market Size - Data Table on Global Anti-CD20 Monoclonal Antibodies (MABs) Market 2019 - 2023 ($ million)
Exhibits 28: Historic Market Size - Product Segment 2019 - 2023 ($ million)
Exhibits 29: Historic Market Size - Type Segment 2019 - 2023 ($ million)
Exhibits 30: Historic Market Size - End-user Segment 2019 - 2023 ($ million)
Exhibits 31: Historic Market Size - Drug Class Segment 2019 - 2023 ($ million)
Exhibits 32: Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
Exhibits 33: Historic Market Size - Geography Segment 2019 - 2023 ($ million)
Exhibits 34: Historic Market Size - Country Segment 2019 - 2023 ($ million)
Exhibits 35: Five forces analysis - Comparison between 2024 and 2029
Exhibits 36: Bargaining power of buyers - Impact of key factors 2024 and 2029
Exhibits 37: Bargaining power of suppliers - Impact of key factors in 2024 and 2029
Exhibits 38: Threat of new entrants - Impact of key factors in 2024 and 2029
Exhibits 39: Threat of substitutes - Impact of key factors in 2024 and 2029
Exhibits 40: Threat of rivalry - Impact of key factors in 2024 and 2029
Exhibits 41: Chart on Market condition - Five forces 2024 and 2029
Exhibits 42: Chart on Product - Market share 2024-2029 (%)
Exhibits 43: Data Table on Product - Market share 2024-2029 (%)
Exhibits 44: Chart on Comparison by Product
Exhibits 45: Data Table on Comparison by Product
Exhibits 46: Chart on Oncology - Market size and forecast 2024-2029 ($ million)
Exhibits 47: Data Table on Oncology - Market size and forecast 2024-2029 ($ million)
Exhibits 48: Chart on Oncology - Year-over-year growth 2024-2029 (%)
Exhibits 49: Data Table on Oncology - Year-over-year growth 2024-2029 (%)
Exhibits 50: Chart on Neurology - Market size and forecast 2024-2029 ($ million)
Exhibits 51: Data Table on Neurology - Market size and forecast 2024-2029 ($ million)
Exhibits 52: Chart on Neurology - Year-over-year growth 2024-2029 (%)
Exhibits 53: Data Table on Neurology - Year-over-year growth 2024-2029 (%)
Exhibits 54: Chart on Immunology - Market size and forecast 2024-2029 ($ million)
Exhibits 55: Data Table on Immunology - Market size and forecast 2024-2029 ($ million)
Exhibits 56: Chart on Immunology - Year-over-year growth 2024-2029 (%)
Exhibits 57: Data Table on Immunology - Year-over-year growth 2024-2029 (%)
Exhibits 58: Market opportunity by Product ($ million)
Exhibits 59: Data Table on Market opportunity by Product ($ million)
Exhibits 60: Chart on Type - Market share 2024-2029 (%)
Exhibits 61: Data Table on Type - Market share 2024-2029 (%)
Exhibits 62: Chart on Comparison by Type
Exhibits 63: Data Table on Comparison by Type
Exhibits 64: Chart on First generation - Market size and forecast 2024-2029 ($ million)
Exhibits 65: Data Table on First generation - Market size and forecast 2024-2029 ($ million)
Exhibits 66: Chart on First generation - Year-over-year growth 2024-2029 (%)
Exhibits 67: Data Table on First generation - Year-over-year growth 2024-2029 (%)
Exhibits 68: Chart on Second generation - Market size and forecast 2024-2029 ($ million)
Exhibits 69: Data Table on Second generation - Market size and forecast 2024-2029 ($ million)
Exhibits 70: Chart on Second generation - Year-over-year growth 2024-2029 (%)
Exhibits 71: Data Table on Second generation - Year-over-year growth 2024-2029 (%)
Exhibits 72: Chart on Third generation - Market size and forecast 2024-2029 ($ million)
Exhibits 73: Data Table on Third generation - Market size and forecast 2024-2029 ($ million)
Exhibits 74: Chart on Third generation - Year-over-year growth 2024-2029 (%)
Exhibits 75: Data Table on Third generation - Year-over-year growth 2024-2029 (%)
Exhibits 76: Market opportunity by Type ($ million)
Exhibits 77: Data Table on Market opportunity by Type ($ million)
Exhibits 78: Chart on End-user - Market share 2024-2029 (%)
Exhibits 79: Data Table on End-user - Market share 2024-2029 (%)
Exhibits 80: Chart on Comparison by End-user
Exhibits 81: Data Table on Comparison by End-user
Exhibits 82: Chart on Hospitals and clinics - Market size and forecast 2024-2029 ($ million)
Exhibits 83: Data Table on Hospitals and clinics - Market size and forecast 2024-2029 ($ million)
Exhibits 84: Chart on Hospitals and clinics - Year-over-year growth 2024-2029 (%)
Exhibits 85: Data Table on Hospitals and clinics - Year-over-year growth 2024-2029 (%)
Exhibits 86: Chart on Academic and research institutions - Market size and forecast 2024-2029 ($ million)
Exhibits 87: Data Table on Academic and research institutions - Market size and forecast 2024-2029 ($ million)
Exhibits 88: Chart on Academic and research institutions - Year-over-year growth 2024-2029 (%)
Exhibits 89: Data Table on Academic and research institutions - Year-over-year growth 2024-2029 (%)
Exhibits 90: Chart on Contract research organizations - Market size and forecast 2024-2029 ($ million)
Exhibits 91: Data Table on Contract research organizations - Market size and forecast 2024-2029 ($ million)
Exhibits 92: Chart on Contract research organizations - Year-over-year growth 2024-2029 (%)
Exhibits 93: Data Table on Contract research organizations - Year-over-year growth 2024-2029 (%)
Exhibits 94: Market opportunity by End-user ($ million)
Exhibits 95: Data Table on Market opportunity by End-user ($ million)
Exhibits 96: Chart on Drug Class - Market share 2024-2029 (%)
Exhibits 97: Data Table on Drug Class - Market share 2024-2029 (%)
Exhibits 98: Chart on Comparison by Drug Class
Exhibits 99: Data Table on Comparison by Drug Class
Exhibits 100: Chart on Rituximab - Market size and forecast 2024-2029 ($ million)
Exhibits 101: Data Table on Rituximab - Market size and forecast 2024-2029 ($ million)
Exhibits 102: Chart on Rituximab - Year-over-year growth 2024-2029 (%)
Exhibits 103: Data Table on Rituximab - Year-over-year growth 2024-2029 (%)
Exhibits 104: Chart on Ofatumumab - Market size and forecast 2024-2029 ($ million)
Exhibits 105: Data Table on Ofatumumab - Market size and forecast 2024-2029 ($ million)
Exhibits 106: Chart on Ofatumumab - Year-over-year growth 2024-2029 (%)
Exhibits 107: Data Table on Ofatumumab - Year-over-year growth 2024-2029 (%)
Exhibits 108: Chart on Obinutuzumab - Market size and forecast 2024-2029 ($ million)
Exhibits 109: Data Table on Obinutuzumab - Market size and forecast 2024-2029 ($ million)
Exhibits 110: Chart on Obinutuzumab - Year-over-year growth 2024-2029 (%)
Exhibits 111: Data Table on Obinutuzumab - Year-over-year growth 2024-2029 (%)
Exhibits 112: Chart on Ublituximab - Market size and forecast 2024-2029 ($ million)
Exhibits 113: Data Table on Ublituximab - Market size and forecast 2024-2029 ($ million)
Exhibits 114: Chart on Ublituximab - Year-over-year growth 2024-2029 (%)
Exhibits 115: Data Table on Ublituximab - Year-over-year growth 2024-2029 (%)
Exhibits 116: Chart on Others - Market size and forecast 2024-2029 ($ million)
Exhibits 117: Data Table on Others - Market size and forecast 2024-2029 ($ million)
Exhibits 118: Chart on Others - Year-over-year growth 2024-2029 (%)
Exhibits 119: Data Table on Others - Year-over-year growth 2024-2029 (%)
Exhibits 120: Market opportunity by Drug Class ($ million)
Exhibits 121: Data Table on Market opportunity by Drug Class ($ million)
Exhibits 122: Chart on Route of Administration - Market share 2024-2029 (%)
Exhibits 123: Data Table on Route of Administration - Market share 2024-2029 (%)
Exhibits 124: Chart on Comparison by Route of Administration
Exhibits 125: Data Table on Comparison by Route of Administration
Exhibits 126: Chart on Intravenous - Market size and forecast 2024-2029 ($ million)
Exhibits 127: Data Table on Intravenous - Market size and forecast 2024-2029 ($ million)
Exhibits 128: Chart on Intravenous - Year-over-year growth 2024-2029 (%)
Exhibits 129: Data Table on Intravenous - Year-over-year growth 2024-2029 (%)
Exhibits 130: Chart on Subcutaneous - Market size and forecast 2024-2029 ($ million)
Exhibits 131: Data Table on Subcutaneous - Market size and forecast 2024-2029 ($ million)

Executive Summary

The following companies are recognized as the key players in the global anti-CD20 monoclonal antibodies (MABs) market: Acrotech Biopharma Inc., Amgen Inc., AstraZeneca PLC, Celltrion Healthcare Co. Ltd., F. Hoffmann La Roche Ltd., Fosun International Ltd., Genmab AS, IGM Biosciences Inc., JSC BIOCAD, LFB SA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Spectrum Pharmaceuticals Inc., TG Therapeutics Inc., United BioPharma Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing awareness about therapeutic areas."

According to the report, one of the major drivers for this market is the increased use of combination therapies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Acrotech Biopharma Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Celltrion Healthcare Co. Ltd.
  • F. Hoffmann La Roche Ltd.
  • Fosun International Ltd.
  • Genmab AS
  • IGM Biosciences Inc.
  • JSC BIOCAD
  • LFB SA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Spectrum Pharmaceuticals Inc.
  • TG Therapeutics Inc.
  • United BioPharma Inc.
  • ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd.

Related Topics

Related Reports

Bispecific Antibodies for Cancer Market 2025-2029 - Product Image

Bispecific Antibodies for Cancer Market 2025-2029

  • Report
  • 233 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Monoclonal Antibodies (MAs) Market Report 2025 - Product Image

Monoclonal Antibodies (MAs) Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Breast Cancer Monoclonal Antibodies Market Report 2025 - Product Image

Breast Cancer Monoclonal Antibodies Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Cancer Monoclonal Antibodies Market by Mechanism Of Action, Target Antigen, Antibody Type, Therapeutic Indication, Route Of Administration, End User, Formulation - Global Forecast to 2030 - Product Image

Cancer Monoclonal Antibodies Market by Mechanism Of Action, Target Antigen, Antibody Type, Therapeutic Indication, Route Of Administration, End User, Formulation - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.